 Ahead of Dato-DXd TL01 study data, expected to be published by AstraZeneca PLC LSE:AZN by the end of Q1 2023, analysts at JPMorgan see a high positive which should unlock multi-blockbuster potential. The analysts said they see a positive readout from the Phase III study in second-line non-small cell lung cancer NSCLC patients, de-risking around 3bn in peak potential in second-line NSCLC. 